Corona Remedies Gears Up for Q3 Reveal on 2nd February; Check Key Expectations Here

Corona Remedies’s Q3 results FY26 are scheduled to be announced on 2nd February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Corona Remedies Q3 Results 2026 Preview

• Corona Remedies’ revenue is expected to be in the range of ₹297.69 crore, a 5.16% YoY decrease. 
• Profit After Tax, or PAT, is projected to rise by 4.63% YoY. 
• Net profit is ₹44.96 crore, a rise 4.63% YoY 
• EBITDA to rise 3.88%

Corona Remedies Share Performance 

• Over the past six months, Corona Remedies’ share price has risen by 1.77% to ₹1,461.90.
• Moreover, over the past year, the stock has increased by 1.63%.
• Despite this weak short-term performance, Corona Remedies’ stock has delivered a financially sound 6.37% return over the past 5 years.
• As of 1st February 2026, the stock traded at ₹1,461.90 per share.

Key Factors to Watch for Corona Remedies Q3 Results FY26 

• Revenue & growth in core therapies: Track top‑line growth, particularly in key therapeutic areas like women’s healthcare, cardio‑diabeto, pain management and urology that drive most sales.
  
• Profitability & margins: Look at EBITDA, EBITDA margins and PAT to see how well the company is converting sales into profits amid cost pressures.
  
• Brand performance & product mix: Performance of “engine” brands (key flagship products) and any expansion of the brand portfolio can affect revenue and earnings quality.
  
• Geographic & market concentration: Commentary on domestic demand trends and diversification beyond concentrated regions, since most revenue comes from India.
  
• Cost & supply dynamics: Watch raw material costs, third‑party supplier dependencies and operating expenses, as these impact margins and execution efficiency.
  

Final Thoughts

Corona Remedies will announce its Q3 FY26 results on 2nd February 2026. Analysts expect 5.16% YoY revenue growth, a 4.63% rise in PAT, and a 3.88% rise in EBITDA. Corona Remedies focuses on manufacturing and marketing branded generic pharmaceuticals across multiple therapeutic segments in India.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Capital Small Finance Bank Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Carborundum Universal Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Capri Global Capital Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Digitide Solutions Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Flair Writing Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

GHCL Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apar Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apollo Pipes Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here